Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$14 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.6
Industry P/E
--
EV/EBITDA
0
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0
Face value
--
Shares outstanding
28,340,812
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Curanex Pharmaceuticals Inc (CURX)
| 48.2 | 8.9 | 48.2 | -- | -- | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Curanex Pharmaceuticals Inc (CURX)
|
0.5 | 13.8 | 0.0 | -1.3 | -- | -17.6 | -- | 0.6 |
| 32.9 | 7,938.3 | 5,355.0 | -98.0 | 9.1 | -1.2 | -- | 1.0 | |
| 18.0 | 827.2 | 1,676.5 | 76.2 | -- | 6.2 | 9.4 | 0.6 |
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including... ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York. Address: 2 Jericho Plaza, Jericho, NY, United States, 11753 Read more
CEO, President & Chairman
Mr. Jun Liu
Secretary
Ms. Dian Ying Jing
Headquarters
Jericho, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Curanex Pharmaceuticals Inc (CURX) is $0.49 (NASDAQ) as of 02-Apr-2026 19:59 EDT. Curanex Pharmaceuticals Inc (CURX) has given a return of --% in the last 1 years.
Since, TTM earnings of Curanex Pharmaceuticals Inc (CURX) is negative, P/E ratio is not available.
The P/B ratio of Curanex Pharmaceuticals Inc (CURX) is 0.56 times as on 31-Mar-2026, a 41 discount to its peers’ median range of 0.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
The 52-week high and low of Curanex Pharmaceuticals Inc (CURX) are Rs 9.18 and Rs 0.27 as of 04-Apr-2026.
Curanex Pharmaceuticals Inc (CURX) has a market capitalisation of $ 14 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Curanex Pharmaceuticals Inc (CURX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.02
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.